New high-density perfusion process produces high quality doses at low cost, and may be applicable to other vaccines
There are many parts of the world where rabies kills as many as
30,000 people a year, according to statistics from the World
A leading vaccine specialist, Eduardo
Aycardi, working under the auspices of the Rockefeller
Foundation, has developed a process for making one million doses
per year of human rabies vaccine.
The main advantage of the
process is that the doses are high quality, but low cost.
Aycardi's process uses Vero cells grown on very high
concentrations (25g/litre) of microcarrier beads.
This is the
first time such high-density perfusion technology has ever been
reported in vaccine production.
The process uses a 30-litre New
Brunswick Scientific cell culture bioreactor run in perfusion
mode, and the technology could easily be applied to vaccine
production for a variety of other diseases, including Japanese
encephalitis, rotavirus, flu, and polio.
manufacturing facilities usually require large numbers of
scientists and large facilities, neither of which are within
economic reach of most developing nations, but Dr Aycardi's
process uses just three lab technicians in a small GMP facility.
Dr Aycardi's paper, 'Producing Human Rabies Vaccines at
Low Cost' is available from New Brunswick Scientific.